logo

Epizyme, Inc. (EPZM)



Trade EPZM now with
  Date
  Headline
11/3/2017 3:18:26 PM Wedbush Is Increasing Epizyme, Inc. (EPZM) FY18 Estimate To -2.15 From -2.18
11/3/2017 3:18:10 PM Wedbush Is Cutting Epizyme, Inc. (EPZM) FY17 Estimate To -2.25 From -2.24
10/27/2017 9:17:52 AM Epizyme Presents Data From Phase1 Trial Of Tazemetostat In Children With Relapsed/Refractory INI1-Negative Solid Tumors
10/25/2017 7:06:08 AM Sierra Oncology Appoints Andrew Allen To Its Board
9/20/2017 6:42:55 AM Jefferies Starts Epizyme, Inc. (EPZM) At Buy With $23 Price Target
9/14/2017 6:31:46 AM Epizyme Reports Pricing Of Public Offering Of 9.18 Mln Shares At $15.25/Shr
9/13/2017 4:03:36 PM Epizyme Announces Proposed Public Offering Of Common Stock
8/15/2017 6:33:35 AM Andrew Singer, EVP, Finance And Administration And CFO Of Epizyme, To Be Leaving At August-end
8/4/2017 6:36:03 AM Epizyme Q2 Net Loss Flat At $28.0 Mln
6/26/2017 6:34:50 AM Epizyme Expands Clinical Collaboration To Study Tazemetostat And TECENTRIQ Combination In NSCLC
6/21/2017 6:32:22 AM Epizyme Says FDA Grants Orphan Drug Designation To Tazemetostat For Treatment Of Soft Tissue Sarcoma
6/14/2017 8:36:15 AM Epizyme Reports Positive Interim Data From Phase 2 Trial For Tazemetostat In Relapsed Or RFL And DLBCL Patients
5/18/2017 3:56:29 PM Wedbush Reiterates Epizyme, Inc. (EPZM) At Outperform With $24 Price Target
5/18/2017 3:55:41 PM Wedbush Is Lowering Epizyme, Inc. (EPZM) 2018 Estimate To -2.15 From -2.09